Relaniya, injection solution, 10 mg / mL ( Torbutrol, Dolorex, TORBUGESIC analog), 10ml

Description

Transparent colorless liquid.

Storage

1 ml of the drug contains the active ingredient:

butorphanol – 10 mg (corresponding to 14.58 mg of butorphanol tartrate).

Excipients: citric acid monohydrate, sodium citrate, sodium chloride, benzethonium chloride, water for injections.

Pharmacological properties

ATCvet classifier: QN02AF01 Butorphanol.

Pharmacodynamics

Butorphanol is an analgesic of the group of synthetic opioids with an agonist-antagonist effect. In addition to pain relief, the drug has a sedative effect, with a possible sedative effect in some animals, depending on the type of animal. This is especially evident when using the drug as part of combined anesthesia and/or neuroleptanalgesia. Breathing slows down, as in the physiological process of an animal falling asleep, and at the same time the number of heart contractions decreases. The duration and intensity of analgesia depends on the dosage and individual sensitivity (increasing the dose or re-introducing the effect of the maximum increase is absent). The effect of the drug occurs after 5-15 minutes, depending on the route of administration, the duration of action depends on the dose (analgesia can last up to 4 hours).

Pharmacokinetics

In horses, butorphanol has a high clearance after intravenous administration (on average 1.3 L/h/kg) and a short terminal half-life (on average less than 1 hour). This indicates that 97% of the active substance is removed from the body in an average of less than 5 hours.

In dogs, after intramuscular administration, the clearance of butorphanol is about 3.5 l/h/kg. The terminal half-life is short (on average less than 2 hours). This indicates that 97% of the active substance is excreted from the body in an average of less than 10 hours. Studies of pharmacokinetics in the regimen of repeated doses and after intravenous administration were not conducted.

In cats, the clearance of butorphanol after subcutaneous administration is low (less than 1.3 l/h/kg). The half-life is relatively long (about 6 hours). This indicates that 97% of the active substance is excreted from the body in about 30 hours.

Pharmacokinetic studies in the regimen of repeated doses were not conducted. Butorphanol is actively metabolized in the liver and excreted with urine and feces. It has a significant distribution in the body with a wide distribution in tissues and organs (liver, kidneys, intestines, lungs, heart, adipose tissue, blood cells). Butorphanol penetrates the placental barrier and is found in the milk of a lactating animal.

Application

Short analgesia for moderate and severe pain (colic, intestinal obstruction, childbirth, post-traumatic pain).

In combination with α2-adrenoceptor agonists (medetomidine, detomidine, romifidine): in therapeutic and diagnostic procedures, such as minor operations on standing animals (castration, hoof care, dental procedures) and sedation of unruly animals.

Dosage

Dogs

Monoanalgesia (intravenous, subcutaneous and intramuscular): 0.2-0.3 ml of the drug per 10 kg of animal body weight (which is equivalent to 0.2-0.3 mg of butorphanol per 1 kg of body weight). Use the drug before the end of anesthesia. For longer analgesia, the dose can be repeated.

As a pre-anesthetic (intravenous, subcutaneous and intramuscular): reduce the dose of the drug to 0.1-0.2 ml per 10 kg of body weight (which is equivalent to 0.1-0.2 mg of butorphanol per 1 kg of body weight) and apply 15 minutes before induction.

As a drug for combined anesthesia

Sedation with medetomidine: 0.1 ml of the drug per 10 kg of body weight (which is equivalent to 0.1 mg of butorphanol per 1 kg of body weight) together with 10-25 μg of medetomidine per 1 kg of body weight (intravenously, intramuscularly). Drugs can be administered simultaneously.

Anesthesia with medetomidine and ketamine: 0.1 ml of the drug per 10 kg of animal body weight (which is equivalent to 0.1 mg of butorphanol per 1 kg of body weight), intramuscularly, 25 μg of medetomidine per 1 kg of animal body weight, intramuscularly. After 15 minutes: 5 mg of ketamine per 1 kg of the animal’s body weight, intramuscularly.

cats

Monoanalgesia

Preoperative analgesia (intravenous, subcutaneous and intramuscular): 0.2 ml of the drug per 5 kg of body weight (which is equivalent to 0.4 mg of butorphanol per 1 kg of body weight) 5 minutes before the administration of acepromazine/ketamine or xylazine/ketamine. With intravenous administration of anesthetic drugs, Relania should be used in a dose of 0.05-0.1 ml (which is equivalent to 0.1-0.2 mg of butorphanol per 1 kg of body weight) 15-30 minutes before anesthetic drugs.

Postoperative analgesia (intravenous, subcutaneous and intramuscular): 0.2 ml of the drug per 5 kg of animal body weight (which is equivalent to 0.4 mg of butorphanol per 1 kg of body weight) 15 minutes before regaining consciousness. For intravenous administration, the drug should be used in a dose of 0.05 ml per 5 kg of animal body weight (which is equivalent to 0.1 mg of butorphanol per 1 kg of body weight).

As a drug for combined anesthesia

Sedation with medetomidine: 0.2 ml of the drug per 5 kg of body weight (which is equivalent to 0.4 mg of butorphanol per 1 kg of body weight) with medetomidine at a dose of 0.05 mg per 1 kg of body weight (intramuscularly, subcutaneously).

Anesthesia with medetomidine and ketamine (intramuscular): 0.2 ml of the drug per 5 kg of body weight (which is equivalent to 0.4 mg of butorphanol per 1 kg of body weight) together with medetomidine (80 mcg per 1 kg of body weight) and ketamine ( 5 mg per 1 kg of body weight). The drug Relania and medetomidine can be administered simultaneously.

Anesthesia with medetomidine and ketamine (intravenous): 0.05 ml of the drug per 1 kg of body weight (which is equivalent to 0.5 mg of butorphanol per 1 kg of body weight) together with medetomidine (40 mcg per 1 kg of body weight) and ketamine (1, 25-2.5 mg per 1 kg of body weight, depending on the required depth of anesthesia). The drug Relania and medetomidine can be administered simultaneously.

Horses

Monoanalgesia

Analgesia (intravenous only): 5 ml of the drug per 500 kg of animal body weight (which is equivalent to 0.1 mg of butorphanol per 1 kg of body weight). If necessary, it is possible to re-introduce the drug. The need and timing of re-administration should be based on the clinical condition of the animal.

As a drug for combined anesthesia

Sedation with detomidine (intravenous only): 12 mcg of detomidine per 1 kg of animal body weight, after which Relania is injected within 5 minutes at the rate of 0.25 ml per 100 kg of animal body weight (which is equivalent to 0.025 mg of butorphanol per 1 kg of body weight) . For horses with a body weight of more than 200 kg, it is advisable to use drugs in the following dose regimen: 1 ml of the drug Relania (which is equivalent to 0.05 mg of butorphanol per 1 kg of body weight) and 25 mcg of detomidine hydrochloride.

Sedation with romifidine (intravenous only): 40-120 mcg of romifidine per 1 kg of animal body weight, 0.2 ml of Relania drug per 100 kg of animal body weight (which is equivalent to 0.02 mg of butorphanol per 1 kg of body weight).

*Kilograms to Pounds conversion table

Contraindication

Hypersensitivity to the active substance or to any other components of the drug, a state of respiratory depression, heart disease, skull injuries, organic brain disorders, functional disorders of the liver and kidneys, convulsions and constipation.

Do not use the drug in combination with a2-adrenoceptor agonists in case of previously known heart arrhythmia in horses. Combined use reduces the motility of the digestive tract, so do not use the drug for colic associated with intestinal obstruction!

Do not use the drug during pregnancy and lactation in all target species of animals!

Do not use for the treatment of productive animals!

Reservation

Before using the drug, it is necessary to carry out a detailed clinical examination of the animal, which will make it possible to better assess any possible risks regarding functional disorders of the cardiovascular system, liver, nervous and respiratory systems. In the latter case, it should be remembered that due to its antitussive properties, butorphanol can lead to the accumulation of mucus in the respiratory tract. Therefore, in animals with respiratory diseases associated with increased mucus production or in animals undergoing treatment with expectorants, butorphanol should only be used based on a risk-benefit analysis by a veterinary specialist.

Stressful factors for animals should be avoided. Follow the rules of asepsis and safe fixation of the animal. Butorphanol should not be mixed with other drugs, with the exception of medetomidine. Do not do combined injections in the same place. The use of butorphanol/detomidine or medetomidine should be avoided in animals with cardiac arrhythmias or bradycardia and in horses prone to colic due to the cardiovascular effects of alpha-2 antagonists.

When using an additional anesthetic, in some cases “starvation” of the animal is required.

Atropine can be used, if necessary, as a typical parasympatholytic. To calculate the dose for small animals, it is necessary to know their exact body weight.

Special precautions for persons and service personnel

Personnel who work with the drug must follow the basic rules of hygiene and safety adopted when working with veterinary drugs. If the drug accidentally gets on the skin or in the eyes, immediately wash it off with water. In case of accidental self-injection, you should immediately consult a doctor and show the leaflet or the label of this drug.

Side effect

All target animal species

When using butorphanol as a monotherapy drug, manifestations of a minor sedative effect are possible.

Horses

Excitement, manifested as a change in the animal’s behavior (the main effect is on the musculoskeletal system), ataxia, decreased motility of the digestive tract, depression of the cardiovascular system.

Dogs

Depression of the respiratory and cardiovascular systems, anorexia and diarrhea, decreased motility of the digestive tract, local pain associated with intramuscular administration.

cats

Mydriasis, disorientation, possible irritation at the injection site in case of repeated injections, dysphoria, excitement, pain during injection.

Interaction with other means and other forms of interaction

Combined use with drugs that are metabolized in the liver can increase the effect of butorphanol. The simultaneous use of butorphanol with anesthetics, central sedatives or depressants of the respiratory system increases their effect. This requires strict control and careful adaptation of the dose. Administering butorphanol to animals that have received an analgesic (a weak c-opiate) can remove its effect.

Overdose (symptoms, emergency measures, antidotes)

Horses:

An increase in the dose may cause respiratory depression, as a common effect of opiates. The antagonist is naloxone, which can be used as an antidote. Other possible signs of overdose include disorders of the central nervous system (excitation, anxiety, slight ataxia and drowsiness), gastrointestinal tract, fever, tachypnea.

Dogs and cats:

Miosis, respiratory depression, hypotension, disorders of the cardiovascular system and, in some cases, apnea, shock and coma. Depending on the clinical condition, the animal must be taken under the supervision of a veterinarian for at least 24 hours.

Release form

1 ml in an ampoule, 5 ampoules in a cassette, 2 cassettes in a pack.

Storage

In the original packaging at a temperature not higher than 25°C.

Shelf life – 2 years.

For use in veterinary medicine!